September 2025 in “International Journal of Molecular Sciences” Deucravacitinib may help treat various immune diseases beyond psoriasis, but more research is needed.
October 2025 in “Zenodo (CERN European Organization for Nuclear Research)” Ritlecitinib may help young adults with severe alopecia areata when ketoconazole fails.
April 2023 in “International Journal of Research in Dermatology” Baricitinib is a promising treatment for severe alopecia areata with minimal side effects.
1 citations
,
January 2026 in “International Journal of Dermatology” Amivantamab can cause severe skin eruptions and scarring, requiring drug discontinuation and early treatment.
June 2025 in “Patient Preference and Adherence” Chinese patients with alopecia areata value JAK inhibitors but worry about side effects and relapse, highlighting the need for education and support.
4 citations
,
January 2014 in “The Journal of urology/The journal of urology” Kidney cancer cells without folliculin are more sensitive to radiation due to increased self-eating cell death.
July 2021 in “Journal of dermatology & dermatologic surgery” IMTA can help regrow hair in severe alopecia areata when JAK inhibitors don't work well.
701 citations
,
August 2014 in “Nature medicine” Alopecia areata can be reversed by JAK inhibitors, promoting hair regrowth.
1 citations
,
July 2025 in “SKIN The Journal of Cutaneous Medicine” Ritlecitinib is effective and safe for long-term treatment of alopecia areata.
January 2018 in “Journal of the advanced practitioner in oncology” Older patients with advanced kidney cancer can be managed with a drug called Sunitinib.
December 2023 in “Acta dermato-venereologica” Tofacitinib is effective for treating alopecia areata, and starting treatment early may improve results.
1 citations
,
September 2022 in “BioNanoScience” Tofacitinib can help hair grow back in alopecia patients but hair loss might return if the dose is lowered.
4 citations
,
February 2018 in “World journal of surgical oncology” A young woman with kidney cancer experienced rare hair loss from a cancer drug and unusual cancer spread, suggesting early drug treatment might reduce spread and prolong survival.
January 2026 in “Experimental Dermatology” Skin-resident memory T cells may contribute to chronic alopecia areata and baricitinib could be a potential treatment.
17 citations
,
January 2019 in “Journal of cutaneous medicine and surgery” JAK inhibitors show promise for treating hair loss in alopecia areata but need more clinical trials to confirm safety and effectiveness.
July 2022 in “Journal of Investigative Dermatology”
January 2022 in “Dermatology Review” EGFR inhibitors can cause unusual localized hair growth.
23 citations
,
March 2017 in “PTR. Phytotherapy research/Phytotherapy research” Butin is effective in treating vitiligo in mice.
February 2016 in “The journal of investigative dermatology/Journal of investigative dermatology” JAK inhibitors may help treat alopecia areata by reversing hair loss.
57 citations
,
August 2006 in “Journal of the American Academy of Dermatology” Gefitinib can cause hair loss without scarring.
July 2024 in “Journal of Investigative Dermatology” ITK inhibitors may effectively treat alopecia areata.
1 citations
,
March 2019 in “Actas Dermo-Sifiliográficas” New cancer treatments are less harmful to hair but can still cause hair loss, color, shape, and growth changes.
70 citations
,
October 2020 in “The journal of allergy and clinical immunology/Journal of allergy and clinical immunology/The journal of allergy and clinical immunology” Janus kinase inhibitors are promising drugs for treating autoimmune and inflammatory diseases.
March 2026 in “Journal of Clinical Oncology” Using 5-α-reductase inhibitors before treatment improves outcomes for patients with metastatic renal cell carcinoma.
July 2024 in “Journal of Investigative Dermatology” Targeting TCR-Vβ2 in cutaneous T cell lymphoma shows promise for safer, more specific treatment.
January 2017 in “Brazilian Journal of Pharmaceutical Sciences” Arteannuin might work against cancer and Alzheimer's by targeting neprilysin.
April 2025 in “Vestnik dermatologii i venerologii” JAK inhibitors like tofacitinib are effective and safer for severe alopecia areata than glucocorticosteroids.
17 citations
,
January 2019 in “Journal of cancer” The formula YH0618 can reduce the harmful side effects of the chemotherapy drug Doxorubicin and protect healthy cells.
January 2018 in “General internal medicine and clinical innovations” Busulfan/cyclophosphamide and total bone irradiation are equally effective for AML transplants.
April 2017 in “The journal of investigative dermatology/Journal of investigative dermatology” Most patients experienced mild to moderate skin problems during a trial for a desmoid tumor treatment.